Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hyperkalemia. Sold as Veltassa. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Patiromer Sorbitex Calcium (sold as Veltassa), first approved Oct 21, 2015, with 2 new uses approved and 0 published complete response letters.
First approved: Oct 21, 2015
Applications: 1
New uses approved: 2
Complete response letters: 0
First approved in Japan: Sep 24, 2024
Medicaid Spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Veltassa
$15.9M for 15,189 prescriptions, -2% on 2024
Where Medicare Prescribes It
163,315 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Hawaii 2.3×, Delaware 1.9×, New Jersey 1.8×
Least
Iowa 0.4×, Arkansas 0.4×, Wisconsin 0.5×
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
VELTASSA 16.8 GM POWDER PACKET: $33.97 per unitBrand · 0% in a year
VELTASSA 8.4 GM POWDER PACKET: $34.02 per unitBrand · +0% in a year
Approvals in Japan (PMDA)
First approved in Japan 107 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Veltassa, new ingredientA drug with a new active ingredient indicated for the treatment of hyperkalaemia. · Zeria Pharmaceutical Co., Ltd. · Sep 24, 2024
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA